Details for Patent: 8,754,123

Which drugs does patent 8,754,123 protect, and when does it expire?

Patent 8,754,123 protects IZBA and is included in one NDA.

This patent has thirty-nine patent family members in twenty-three countries.

Summary for Patent: 8,754,123

Title:	Pharmaceutical compositions having desirable bioavailability
Abstract:	The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.
Inventor(s):	Kabra; Bhagwati P. (Euless, TX)
Assignee:	Alcon Research, Ltd. (Fort Worth, TX)
Application Number:	13/442,475
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,754,123
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,754,123

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	IZBA	travoprost	SOLUTION/DROPS;OPHTHALMIC	204822-001	May 15, 2014		DISCN	Yes	No			Y

International Family Members for US Patent 8,754,123

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	070888
Argentina	124058
Australia	2009225824
Brazil	PI0908717
Canada	2716994
Chile	2009000624